Also known as: Erbitux (brand)
Cetuximab is a chimeric IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is used in the treatment of KRAS wild-type metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). It inhibits tumor cell proliferation by blocking EGFR signaling. Mediocon Inc supplies pharmaceutical-grade Cetuximab API for oncology drug manufacturers.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Purity | ≥ 98% (by SEC-HPLC) |
| Endotoxin | NMT 1 EU/mg |
| Bioburden | Complies |
| Identification | Peptide Mapping Compliant |
| Storage | 2–8°C |
| Packing | As per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Cetuximab (CAS 205923-56-4) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Cetuximab is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance